Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
deals
life sciences
national blog main
san francisco
3
×
san francisco blog main
san francisco top stories
startups
3
×
acetylon pharmaceuticals
ambys medicines
boston blog main
boston top stories
cell therapy
constellation pharmaceuticals
fda
food and drug administration
gene therapy
genentech
genetic testing
holger willenbring
invitae
ipo
jeffrey tong
juan carlos izpisua belmonte
keith dionne
liver disease
markus grompe
martin burke
medical device
national top stories
new york blog main
new york top stories
non-invasive prenatal tests
oregon stem cell center
prenatal tests
proteon therapeutics
pulmonary arterial hypertension
raleigh-durham blog main
salk institute for biological studies
san diego blog main
What
deal
3
×
ability
acquire
aiming
ambys
array
babies
big
bio
biotech
building
business
control
cost
deadly
debuted
developer
disease
diseases
drug
established
expand
firm
formed
future
genetic
invitae
launch
liver
low
lung
make
maker
medical
medicines
momentum
new
offers
pah
prenatal
Language
Current search:
xconomy.com
×
deal
×
biotech
×
startups
×
" san francisco "
×
@xconomy.com
4 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed